This record provides bibliographic details and links to the original research. An editorial study breakdown is not available.
Torkelson et al. (2012) · ISRN Oncology
- Population
- 11 women with stage I-III breast cancer enrolled after surgery, chemotherapy, and radiotherapy; 9 completed the dose-escalation phase
- Intervention
- Oral freeze-dried turkey tail mycelial powder at 3, 6, or 9 g/day for 6 weeks, followed by a 3-week washout
- Comparator
- No placebo or randomized control. Some immune analyses were contextualized against a separate observational recovery cohort from the same centers.
- Finding
- The clearest takeaway is tolerability up to 9 g/day plus early immune-recovery signals, not proof of better breast-cancer outcomes.
preliminary This is now a full-text-reviewed page, but the study itself remains a very small open-label phase 1 trial.
Torkelson et al. (2012), PMCID PMC3369477
Key Numbers
The numbers most worth remembering
9/11
Completed
Two withdrawals after visit 2
9 g/day
Highest published dose
Taken for 6 weeks after radiotherapy
20%
Lymphocyte drop after RT
1.027 to 0.681 thou/uL; P < .001
P = .0003
CD8+ dose signal
9 g/day outperformed 3 g/day and 6 g/day
The most exact pre/post-radiotherapy numbers come from a pooled 23-patient dataset, not a randomized turkey-tail comparison. That matters when you interpret how strong the mushroom claim really is.
Torkelson et al. (2012), full paper
- Before RT
Eligibility and enrollment
- Women aged 21 to 75 with stage I to III breast cancer were enrolled after surgery and chemotherapy and before radiotherapy.
- The study ran at the University of Minnesota and Bastyr University.
- Post-RT baseline
Immune status measured after standard treatment
- Researchers collected CBC, NK-cell activity, and lymphocyte subset data after radiotherapy.
- The paper uses these post-radiotherapy deficits as the biological problem turkey tail might help address.
- Weeks 1 to 6
Sequential dose-escalation cohorts
- Three women each received 3 g/day, 6 g/day, or 9 g/day in divided oral doses.
- Adverse events were screened weekly with CTCAE v3.0 criteria.
- Week 9
Washout and follow-up
- Participants stopped product use for 3 weeks after treatment.
- The protocol planned higher doses, but the published paper reports only the 3, 6, and 9 g/day cohorts.
Torkelson et al. (2012), Figure 1 and Methods
What This Study Actually Asked
This paper is easiest to misread if you approach it like a breast-cancer efficacy trial. It was not built for that.
The real question was narrower: after standard treatment, can women recently through radiotherapy take oral turkey tail safely for six weeks, and do any immune markers move enough to justify more serious follow-up research?
That is still a useful question. It is just a different question from whether turkey tail lowers recurrence risk, improves survival, or meaningfully changes symptoms.
What The Full Paper Adds
The full paper is much more helpful than the abstract alone because it shows exactly where the study is sturdy and where it is fragile.
- The trial was open-label and sequential, not randomized.
- There was no placebo or concurrent control arm.
- Two women withdrew after visit two because transportation to the clinic was too difficult.
- One participant who completed the study had not received chemotherapy before radiation, which the paper reports as an eligibility protocol violation.
- The product was a specific freeze-dried Trametes versicolor mycelial powder obtained from Fungi Perfecti and encapsulated by Beehive Botanicals.
- Weekly adverse-event checks were built into the protocol, which matters because safety was the real primary endpoint.
Those details make the paper more credible on tolerability than on efficacy.
Key Findings And How To Read Them
| Finding | What the paper reports | How to read it |
|---|---|---|
| Safety | Nine adverse events total: 7 mild, 1 moderate, 1 severe. The published cohorts were described as tolerating up to 9 g/day. | This supports short-term tolerability in a tiny post-radiotherapy sample. It does not prove the regimen would stay benign in broader or longer-term use. |
| Lymphocyte recovery | In the pooled 23-patient observational-plus-trial dataset, mean lymphocyte count fell from 1.027 +/- 0.298 before radiotherapy to 0.681 +/- 0.254 after radiotherapy, P < .001. The 6 g/day and 9 g/day cohorts then appeared to recover faster. | The exact number mainly proves that radiotherapy depressed immune cell counts in this population. It is weaker evidence that turkey tail caused the later recovery pattern. |
| NK-cell activity | In the same pooled dataset, NK activity fell from 19.941 +/- 18.959 before radiotherapy to 9.872 +/- 13.454 after radiotherapy, P = .043. A temporary upward trend was most visible in the 6 g/day cohort. | This is biologically interesting, but it is still a surrogate marker, not a patient outcome. |
| CD8+ T cells | Across treatment weeks 2, 4, and 6, the 9 g/day cohort showed higher CD8+ counts than the 3 g/day and 6 g/day cohorts, F(2, 6) = 42.04, P = .0003. | This is the paper's sharpest direct dose-group signal. It is still based on only three women per cohort. |
| CD19+ B cells | The 6 g/day cohort showed a higher CD19+ B-cell signal than the 3 g/day cohort, F(2, 6) = 6.312, P = .0334. | The immune story is not a simple more-dose-is-better line, which is one reason to keep the interpretation cautious. |
One practical detail the full paper adds is that nausea and GI upset were not reported, which matters because tolerability claims are common in mushroom marketing and rarely pinned to actual adverse-event tables.
One detail worth keeping visible is that the paper is slightly messy on the severe anxiety event: the adverse-event table lists it as possibly related, while the discussion text describes it as likely unrelated. That kind of inconsistency does not overturn the paper, but it is exactly the sort of thing a careful reader should notice.
Methods Audit
Methods Audit
Where the design is strong enough and where it is weak
Randomization and blinding: absent
This was an open-label sequential dose-escalation study, not a randomized or blinded trial.
Comparator quality: weak
There was no placebo arm. Some analyses were contextualized against a separate observational cohort, which helps biologically but does not fix the causal problem.
Analysis population: tiny
The dose-escalation phase finished with 9 completers, leaving only 3 women per dose cohort.
Adverse-event capture: decent for a phase 1 paper
Participants were screened weekly in clinic or by phone using CTCAE v3.0 and dose-limiting-toxicity criteria.
Preregistration: not clearly public
The paper reports FDA IND approval (#75,405), but it does not provide a public trial-registration record.
Torkelson et al. (2012), Methods and Results
Why This Study Matters
Even with those limitations, this paper still matters for the breast-cancer turkey-tail literature.
It gives the field something more concrete than vague "immune support" language:
- a defined patient population
- a defined post-radiotherapy window
- actual dose cohorts
- weekly safety monitoring
- repeated immune measurements over time
That is real progress. It is just early progress.
Reasons This Study Might Be Wrong
Skeptical Read
The main reasons not to over-update on this paper
Three women per cohort is not enough
Apparent dose-response patterns can look cleaner than they really are when the groups are this small.
The strongest exact numbers are not from a randomized turkey-tail comparison
The paper's pre/post-radiotherapy lymphocyte and NK-cell numbers come from pooling the 9-patient trial with a 14-patient observational cohort.
Immune markers are not breast-cancer outcomes
Nothing here demonstrates tumor response, disease-free survival, overall survival, or symptom improvement.
One protocol violation and two practical dropouts matter in a study this small
A tiny uncontrolled trial has very little margin for baseline imbalance or data fragility.
This was a specific product, not 'all turkey tail'
The findings apply most directly to the studied freeze-dried mycelial preparation, not every retail capsule or extract.
Torkelson et al. (2012), full paper
What Happened Next
- 2012
The study entered the literature as a safety and immune-signal paper
- Its most defensible contribution was showing that oral turkey tail looked tolerable up to 9 g/day in this post-radiotherapy setting.
- It did not settle whether turkey tail improves clinical breast-cancer outcomes.
- 2024
NCI still described the breast-cancer evidence as immune-parameter focused
- The NCI PDQ health professional summary said breast-cancer studies of Trametes versicolor products have focused on immune changes rather than survival or symptom endpoints.
- 2024 to 2026
A phase II presurgical breast-cancer trial opened
- NCI lists an active phase II trial of Coriolus versicolor extract in post-menopausal ER-positive, HER2-negative breast cancer (NCT06450873).
- That is a sign the field is still moving, but also a sign that this 2012 paper never became definitive on its own.
- 2025
A dedicated breast-cancer review still called the human evidence thin
- A 2025 review identified 11 original breast-cancer studies from 2010 to 2025 across cell, animal, and human work, but only one phase 1 clinical trial.
- The review still called for larger placebo-controlled trials.
NCI PDQ (updated 2024); NCI trial listing NCT06450873; Ziaja-Soltys and Jaszek (2025)
The short version is that this study still looks historically important, but not definitive. It helped establish that the question was worth asking in humans. It did not answer the question in a way that closes the case.
If you want the field-level context directly, see the NCI PDQ mushrooms summary, the active NCI phase II turkey tail breast-cancer listing, and the 2025 breast-cancer review.
Funding And Conflicts
The paper credits funding from the National Institutes of Health / National Center for Complementary and Alternative Medicine and from Gateway for Cancer Research. The authors reported no conflicts of interest.
That does not remove bias risk entirely, but it is a better funding profile than the supplement-sponsored evidence readers often expect in this space.
Rethink Takeaway
The best reading of this paper is disciplined and modest: in women who had recently completed radiotherapy for breast cancer, a specific oral turkey-tail mycelium preparation looked tolerable up to 9 g/day and produced several immune signals worth following up.
That is meaningful. It is also far short of showing that turkey tail improves breast-cancer prognosis.
If this study changes your mind, it should move you from "there is no serious human work here" to "there is an early human signal worth tracking." It should not move you to "turkey tail works for breast cancer."
Read the original research
Phase 1 Clinical Trial of Trametes versicolor in Women with Breast Cancer.
ISRN oncology, 2012, 251632
Citation
Torkelson, Carolyn J; Sweet, Erin; Martzen, Mark R; Sasagawa, Masa; Wenner, Cynthia A; Gay, Juliette; Putiri, Amy; Standish, Leanna J. (2012). Phase 1 Clinical Trial of Trametes versicolor in Women with Breast Cancer.. ISRN oncology, 2012, 251632. https://doi.org/10.5402/2012/251632